{"id":38378,"date":"2025-08-20T10:06:02","date_gmt":"2025-08-20T08:06:02","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/?p=38378"},"modified":"2025-08-15T12:50:30","modified_gmt":"2025-08-15T10:50:30","slug":"neue-daten-zum-pcsk9-hemmer-inclisiran-cme","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2025\/neue-daten-zum-pcsk9-hemmer-inclisiran-cme","title":{"rendered":"Neue Daten zum PCSK9-Hemmer Inclisiran [CME]"},"content":{"rendered":"<p>Inclisiran (Inc; Handelsname Leqvio\u00ae) ist ein Hemmstoff der Proproteinkonvertase Subtilisin\/Kexin Typ\u00a09 (PCSK9). Dieses Enzym ist ma\u00dfgeblich am Abbau des \u201eLow Density Lipoprotein\u201c-Rezeptors\u201c (LDLR) beteiligt und somit an der Regulation des intrazellul\u00e4ren Cholesterinstoffwechsels. Die Hemmung von PCSK9 wird seit rund 10\u00a0Jahren therapeutisch genutzt: monoklonale Antik\u00f6rper (mAK) wie Evolocumab und Alirocumab binden an zirkulierende PCSK9 und neutralisieren [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Inclisiran (Inc; Handelsname Leqvio\u00ae) ist ein Hemmstoff der Proproteinkonvertase Subtilisin\/Kexin Typ\u00a09 (PCSK9). Dieses Enzym ist ma\u00dfgeblich am Abbau des \u201eLow Density Lipoprotein\u201c-Rezeptors\u201c (LDLR) beteiligt und somit an der Regulation des intrazellul\u00e4ren Cholesterinstoffwechsels. Die Hemmung von PCSK9 wird seit rund 10\u00a0Jahren therapeutisch genutzt: monoklonale Antik\u00f6rper (mAK) wie Evolocumab und Alirocumab binden an zirkulierende PCSK9 und neutralisieren [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[1272,1274,6242,456,1525,1522,6243],"class_list":["post-38378","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-arteriosklerose","tag-cholesterin","tag-incilisiran","tag-lipidsenker","tag-pcsk9","tag-pcsk9-hemmer","tag-victorion-mono-studie"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/38378","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=38378"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/38378\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=38378"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=38378"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=38378"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}